FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA Preliminary Results From a Phase I/II Clinical Treatment Trial

Nti Akosua A.; Serrano Leona W.; Sandhu Harpal S.; Uyhazi Katherine E.; Edelstein Ilaina D.; Zhou Elaine J.; Bowman Scott; Song Delu; Gangadhar Tara C.; Schuchter Lynn M.; Mitnick Sheryl; Huang Alexander; Nichols Charles W.; Amaravadi Ravi K.; Kim Benjamin J.; Aleman Tomas S.

首页> 外文期刊>Retina >FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA Preliminary Results From a Phase I/II Clinical Treatment Trial

【24h】

FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA Preliminary Results From a Phase I/II Clinical Treatment Trial

机译：使用高剂量羟基氯喹的常见的亚临床性黄斑变化与高剂量羟氯喹，作为治疗前期临床治疗试验的先进转移性BRAF突变体黑素瘤的初步结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: To assess the potential ocular toxicity of a combined BRAF inhibition (BRAFi) + MEK inhibition (MEKi) + hydroxychloroquine (HCQ) regime used to treat metastatic BRAF mutant melanoma.

机译：目的：评估组合BRAF抑制（BRAFI）+ MEK抑制（MEKI）+羟基氯喹（HCQ）制度的潜在眼镜毒性用于治疗转移性BRAF突变体黑素瘤。

著录项

来源
《Retina》 |2019年第3期|共12页
作者
Nti Akosua A.; Serrano Leona W.; Sandhu Harpal S.; Uyhazi Katherine E.; Edelstein Ilaina D.; Zhou Elaine J.; Bowman Scott; Song Delu; Gangadhar Tara C.; Schuchter Lynn M.; Mitnick Sheryl; Huang Alexander; Nichols Charles W.; Amaravadi Ravi K.; Kim Benjamin J.; Aleman Tomas S.;
展开▼
作者单位

Univ Penn Perelman Sch Med Dept Ophthalmol Perelman Ctr Adv Med Scheie Eye Inst Philadelphia;

Univ Penn Perelman Sch Med Dept Ophthalmol Perelman Ctr Adv Med Scheie Eye Inst Philadelphia;

Univ Penn Perelman Sch Med Dept Ophthalmol Perelman Ctr Adv Med Scheie Eye Inst Philadelphia;

Univ Penn Perelman Sch Med Dept Ophthalmol Perelman Ctr Adv Med Scheie Eye Inst Philadelphia;

Univ Penn Perelman Sch Med Dept Ophthalmol Perelman Ctr Adv Med Scheie Eye Inst Philadelphia;

Univ Penn Perelman Sch Med Dept Ophthalmol Perelman Ctr Adv Med Scheie Eye Inst Philadelphia;

Univ Penn Perelman Sch Med Dept Ophthalmol Perelman Ctr Adv Med Scheie Eye Inst Philadelphia;

Univ Penn Perelman Sch Med Dept Ophthalmol Perelman Ctr Adv Med Scheie Eye Inst Philadelphia;

Univ Penn Perelman Sch Med Dept Med Abramson Canc Ctr Philadelphia PA 19104 USA;

Univ Penn Perelman Sch Med Dept Med Abramson Canc Ctr Philadelphia PA 19104 USA;

Univ Penn Perelman Sch Med Dept Med Abramson Canc Ctr Philadelphia PA 19104 USA;

Univ Penn Perelman Sch Med Dept Med Abramson Canc Ctr Philadelphia PA 19104 USA;

Univ Penn Perelman Sch Med Dept Ophthalmol Perelman Ctr Adv Med Scheie Eye Inst Philadelphia;

Univ Penn Perelman Sch Med Dept Med Abramson Canc Ctr Philadelphia PA 19104 USA;

Univ Penn Perelman Sch Med Dept Ophthalmol Perelman Ctr Adv Med Scheie Eye Inst Philadelphia;

Univ Penn Perelman Sch Med Dept Ophthalmol Perelman Ctr Adv Med Scheie Eye Inst Philadelphia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词
MEK; hydroxychloroquine; interdigitation zone; outer segments; optical coherence tomography; central serous retinopathy; cutaneous melanoma; BRAF inhibition; MEK inhibition; photoreceptors; subretinal fluid;

机译：梅克;羟氯喹;区段;外部段;光学相干断层扫描;中央浆膜视网膜病;皮肤黑色素瘤;BRAF抑制;MEK抑制;感光体;镜片;

相似文献

外文文献
中文文献
专利

1. FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA Preliminary Results From a Phase I/II Clinical Treatment Trial [J] . Nti Akosua A., Serrano Leona W., Sandhu Harpal S., Retina . 2019,第3期

机译：使用高剂量羟基氯喹的常见的亚临床性黄斑变化与高剂量羟氯喹，作为治疗前期临床治疗试验的先进转移性BRAF突变体黑素瘤的初步结果
2. Frequent subclinical macular changes in melanoma patients treated with combined BRAF/MEK inhibition and high dose hydroxychloroquine does not require dosing modification or discontinuation: preliminary results from a multi-institutional phase I/II clinical treatment trial for advanced metastatic BRAF mutant melanoma [J] . Serrano Leona, Sandhu Harpal, Zhou Elaine, Investigative ophthalmology & visual science . 2017,第8期

机译：使用组合BRAF / MEK抑制和高剂量羟基氯喹处理的黑色素瘤患者的常见亚临床黄斑变化不需要给药改性或停药：来自多制剂期I / II临床治疗试验的初步结果，用于先进的转移BRAF突变体黑素瘤
3. Frequent subclinical macular changes in melanoma patients treated with combined BRAF/MEK inhibition and high dose hydroxychloroquine does not require dosing modification or discontinuation: preliminary results from a multi-institutional phase I/II clinical treatment trial for advanced metastatic BRAF mutant melanoma [J] . Serrano Leona, Sandhu Harpal, Zhou Elaine, Investigative ophthalmology & visual science . 2017,第8期

机译：使用组合BRAF / MEK抑制和高剂量羟基氯喹处理的黑色素瘤患者的常见亚临床黄斑变化不需要给药改性或停药：来自多制剂期I / II临床治疗试验的初步结果，用于先进的转移BRAF突变体黑素瘤
4. Preliminary results of a phase I/II clinical trial using in situ photoimmunotherapy combined with imiquimod for metastatic melanoma patients [C] . Xiaosong Li, Mark F. Naylor, Robert E. Nordquist, . 2010

机译：使用原位光免疫疗法联合咪喹莫特治疗转移性黑色素瘤患者的I / II期临床试验的初步结果
5. Phase II double-blinded randomized controlled clinical trial of chondroitinase ABC by intraspinal injection for treatment of severe chronic spinal cord injury in 60 pet dogs. [D] . Hu, Hilary. 2016

机译：脊髓内注射软骨素酶ABC的II期双盲随机对照临床试验，用于治疗60只宠物狗的严重慢性脊髓损伤。
6. FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA [O] . Akosua A. Nti, Leona W. Serrano, Harpal S. Sandhu, -1

机译：BRAF / MEK联合抑制与高剂量羟氯喹联合治疗晚期转移性BRAF突变性黑素瘤的频次亚临床黄斑改变
7. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor [O] . Kim, Kevin B, Kefford, Richard, Gonzalez, Rene, 2013

机译：MEK1 / MEK2抑制剂曲美替尼在先前接受或不接受BRAF抑制剂治疗的转移性BRAF突变型皮肤黑色素瘤患者中的II期研究

FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA Preliminary Results From a Phase I/II Clinical Treatment Trial

摘要

著录项

相似文献

相关主题

期刊订阅